EX-FILING FEES 5 d233210dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

CALCULATION OF FILING FEE TABLES

Form S-3

(Form Type)

IGM Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

                 
     Security
Type
  Security
Class
Title
  Fee
Calculation
Rule
  Amount
Registered
  Proposed
Maximum
Offering
Price Per
Unit
  Maximum
Aggregate
Offering
Price
 

Fee

Rate

  Amount of
Registration
Fee
                 
Fees to Be
Paid
  Equity   Common Stock, par value $0.01 per share   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Equity   Non-Voting Common Stock, par value $0.01 per share   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Equity   Preferred Stock, par value $0.01 per share   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Debt   Debt Securities   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Equity   Depositary Shares   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Equity   Warrants   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Other   Subscription Rights   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Other   Purchase Contracts   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Other   Units   Rule 457(o)   (1)   (1)   (1)   —     —  
                 
Fees to Be
Paid
  Unallocated (Universal) Shelf   Unallocated (Universal) Shelf   Rule 457(o)   (1)   (1)   $400,000,000   0.0001476   $59,040
           
    Total Offering Amounts      $400,000,000     $59,040
           
    Total Fees Previously Paid         
           
    Total Fee Offsets         
           
    Net Fee Due                $59,040

 

(1)

An indeterminate aggregate initial offering price and number of securities of each identified class is being registered as may from time to time be offered, issued or sold at indeterminate prices. In addition, an indeterminate number of securities that may be issued upon exercise, settlement, conversion or exchange of any offered securities, or pursuant to anti-dilution adjustments, is being registered. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities.